First Wave BioPharma, Inc. (FWBI)
- Previous Close
2.9900 - Open
3.0500 - Bid 2.1600 x 200
- Ask 3.5800 x 200
- Day's Range
2.8400 - 3.0743 - 52 Week Range
2.3340 - 60.0000 - Volume
8,994 - Avg. Volume
86,732 - Market Cap (intraday)
5.752M - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
-- - EPS (TTM)
-47.8800 - Earnings Date May 14, 2024 - May 22, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
36.00
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
www.firstwavebio.comRecent News: FWBI
Performance Overview: FWBI
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FWBI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FWBI
Valuation Measures
Market Cap
6.06M
Enterprise Value
3.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-159.98%
Return on Equity (ttm)
-497.87%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-16.1M
Diluted EPS (ttm)
-47.8800
Balance Sheet and Cash Flow
Total Cash (mrq)
3.71M
Total Debt/Equity (mrq)
22.95%
Levered Free Cash Flow (ttm)
-7.76M
Research Analysis: FWBI
Company Insights: FWBI
FWBI does not have Company Insights